cobas® BKV

Quantitative nucleic acid test for use on the cobas® 5800/6800/8800 systems
IVD For in vitro diagnostic use.

Setting a new standard for transplant patients

BK Polyomavirus (BKPyV) is a significant pathogen in transplant recipients, where viral reactivation can lead to serious complications such as polyomavirus-associated nephropathy (PVAN) and hemorrhagic cystitis, posing a direct threat to allograft survival and patient health.1,2 Early detection with best-in-class monitoring tools provides actionable results, enabling informed treatment decisions.

The cobas® BKV test provides reliable, standardized, high-quality results for the improved management of transplant patients at risk of infection. The BKV test is intended for use as an aid in the management of BKV in kidney and hematopoietic stem cell transplant patients, with results used to indicate the need for potential treatment changes.3 The test is for use on the automated cobas® 5800/6800/8800 systems.

Benefits at a glance<sup>3</sup>

Benefits at a glance3

Acronym ‘WHO’ combined with a tick, illustrating that cobas BKV results are traceable to WHO international standards

Results traceable to the WHO International Standard and reporting in IU/mL for improved harmonization in testing results across hospitals and institutions.

Target with tick icon, illustrating the reliable and reproducible results of the cobas BKV assay

A dual target assay design to provide reliable and reproducible results for reassurance in clinical decision making.

Twisting arrow icon, illustrating the flexibility of BKV testing on the cobas 5800/6800/8800 Systems

Ability to perform critical transplant testing (CMV, EBV, BKV) from a single sample on the cobas 5800/6800/8800 systems with an industry-leading menu, absolute automation, and proven performance.

Liquid sample, test tube icon, illustrating the stability of urine samples in cobas PCR media

Urine sample stabilized in cobas® PCR media allows result integrity to be maintained, enabling faster preparation and making storage and transportation more convenient without the need for refrigeration.

cobas BKV test for cobas 5800/6800/8800 systems performance3

View full table

cobas BKV test for cobas 5800/6800/8800 systems performance3

Product specification

Value

Dual assay targets

VP2 and small t-Antigen

Sample types

EDTA Plasma

Urine stabilized in cobas® PCR media

Minimum amount of sample required

EDTA Plasma: 350 µL

Urine: 550 µL

Sample processing volume

EDTA Plasma: 200 µL

Urine: 400 µL

Analytical sensitivity

EDTA Plasma: 21.5 IU/mL (95% CI 16.3 IU/mL - 32.4 IU/mL)

Urine: 12.2 IU/mL (95% CI 9.2 IU/mL - 18.3 IU/mL)

Linear range

EDTA Plasma: 21.5 IU/mL to 1E+08 IU/mL

Urine: 200 IU/mL to 1E+08 IU/mL

Overall precision

EDTA Plasma: SD 0.03 - 0.13 log10

Urine: SD 0.02 - 0.07 log10

Subtypes detected

Subtypes I (Ia, Ib, and Ic), II, III and IV

Use left and right arrow keys to scroll between the tabs

Overview

Ordering information

error errorMessage
Sorry, we couldn't find the content you are looking for
Please try again later

Compatible products

No products found for this filter.

Related products

Contact us

Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.

References

  1. Hirsch HH, Randhawa PS; AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13528.
  2. Tomblyn M, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant. 2009;44:453-5.
  3. F. Hoffmann-La Roche Ltd. cobas® BKV quantitative nucleic acid test for use on cobas® 5800/6800/8800 systems (Package insert 09478124001-04EN).